Nutriband secures $2 million line of credit financing facility to be used for commercialization of aversa(tm) abuse-deterrent transdermal technology

Orlando, fl / accesswire / march 28, 2023 / nutriband inc. ("company") (nasdaq:ntrb)(nasdaq:ntrbw) has entered into a three-year $2,000,000 credit line facility to provide financing through the fda approval process into commercial scale manufacturing for the company's patented lead product, aversa™ fentanyl, an abuse-deterrent fentanyl transdermal system. aversa™ fentanyl contains nutriband's proprietary transdermal abuse deterrent technology.
NTRB Ratings Summary
NTRB Quant Ranking